Fifty-eight patients suspected of having focal hepatic disease were st
udied prior to and following the intravenous administration of mangane
se (II) N,N'-dipyridoxylethylenedi-amine-N,N'-diacetate 5,5'-bis(phosp
hate) (DPDP), a hepatobiliary magnetic resonance (MR) contrast agent.
Four doses (3, 5, 8, or 10 mumol/kg) of Mn-DPDP were used to test the
hypothesis that Mn-DPDP-enhanced MR imaging would display enhancement
in tumors of hepatocellular origin. A total of 203 lesions were evalua
ted. Histologic proof was available in 32 cases, and in 26 cases lesio
ns were evaluated on the basis of characteristic imaging findings. Sta
tistical calculations for distinction of tumors of hepatocellular orig
in yielded a sensitivity of 100%, a specificity of 92.0%, an accuracy
of 93.6%, a positive predictive value of 75.9%, and a negative predict
ive value of 100%. The authors conclude that the presence and patterns
of enhancement at Mn-DPDP-enhanced MR imaging permit reliable distinc
tion between hepatocellular and nonhepatocellular tumors.